DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Down 71.2% in April

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 161,900 shares, a decline of 71.2% from the March 31st total of 561,900 shares. Currently, 0.6% of the company's stock are sold short. Based on an average daily volume of 395,800 shares, the days-to-cover ratio is currently 0.4 days.

DBV Technologies Stock Down 4.2 %

NASDAQ:DBVT traded down $0.37 during trading hours on Friday, hitting $8.53. 73,375 shares of the stock traded hands, compared to its average volume of 183,871. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.59. The stock has a 50 day moving average price of $5.91 and a 200 day moving average price of $4.48. The company has a market cap of $175.48 million, a price-to-earnings ratio of -1.90 and a beta of -0.08.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. Equities analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on DBVT shares. JMP Securities reissued a "market outperform" rating and set a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th. StockNews.com started coverage on DBV Technologies in a report on Wednesday. They set a "hold" rating on the stock.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.